XBRANE BIOPHARMA'S PRINCIPAL OWNER SYSTEMATIC GROUP PROVIDES A SHORT-TERM LOAN OF SEK 20 M TO THE COMPANY

MAR

Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has today received a short-term loan from Systematic Group AB ("Systematic Group") of SEK 20 million (the "Loan").

The loan provided by Systematic Group amounts to SEK 20 million and runs for approximately 1 month until the expected up-front payment of €10 million from Intas Pharmaceuticals Ltd, in accordance with the previously communicated license agreement for Xdivane (Opdivo biosimilar candidate), is received. Interest is charged at 1 percent per month. The loan will finance the company's working capital needs until the above-mentioned up-front payment is received.

Datum 2024-12-02, kl 14:30
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!